Recently, ORATS founder Matt Amberson was interviewed by Jill Maladrino on TradeTalks. Matt...Read More
Celgene (CELG) is to be bought by Bristol-Myers Squibb (BMY) at a 54% premium to the closing...Read More
Listen to the latest episode of The Advisor's Option, by Mark Longo of the Option Insider,...Read More
ORATS has a way to remove the effect of earnings announcements on implied volatility (IV).Read More
ORATS data and comments appeared in a Reuters story on Tesla yesterday.Read More
Get started backtesting options strategies and improve your options knowledge. You will get a...Read More
Get us in your inbox.